Compare Expeditors International of Wshngtn Inc (EXPD) vs 10X Genomics Inc (TXG) Price & Performance

EXPD trades at $193.71, up 1.5% with a bullish technical signal supported by moving averages. The company demonstrates strong profitability with 7.63% net income margin and exceptional ROE of 42.6%, though revenue growth remains modest. Recent earnings beats and positive analyst coverage highlight operational strength amid resilient airfreight demand and efficiency initiatives.

While valuation multiples appear elevated (P/E 28.2), consistent earnings outperformance and institutional interest support upside potential. Key risks include freight market volatility and competitive pressures. The consensus price target of $179.43 suggests modest downside from current levels, requiring careful risk-reward assessment.

TXG trades at $80.65, up 5.98% on the day, showing strong recent momentum despite a bearish technical signal. The company reported revenue of $642.82M for 2025 with a gross margin of 70.03%, but remains unprofitable with a net loss of $43.54M. Recent news highlights the launch of the Atera spatial biology platform and a patent victory, signaling innovation and competitive strength. Analyst consensus is mixed with a $74.30 price target below the current price, indicating caution on valuation.

The outlook for TXG hinges on commercial execution of new products like Atera to drive revenue growth and a path to profitability. Investment opportunity lies in its leading technology platform and expanding market demand in genomics. Key risks include persistent losses, high valuation multiples, and competitive pressures in the life sciences tools sector. The stock's recent rally faces a test near technical resistance at $81.